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AbstrAct
The spread of pandemic COVID-19 has created 
unprecedented need for information. The 
pandemic is the cause of significant mortality 
and with this the need for rapidly disseminated 
information for palliative care professionals 
regarding the prevalence of symptoms, their 
intensity, their resistance or susceptibility to 
symptom control and the mode of death for 
patients.
Methods We undertook a systematic review 
of published evidence for symptoms in patients 
with COVID-19 (with a specific emphasis on 
symptoms at end of life) and on modes of death. 
Inclusion: prospective or retrospective studies 
detailing symptom presence and/or cause or 
mode of death from COVID-19.
results 12 papers met the inclusion criteria and 
gave details of symptom burden: four of these 
specifically in the dying and two detailed the 
cause or mode of death. Cough, breathlessness, 
fatigue and myalgia are significant symptoms in 
people hospitalised with COVID-19. Dyspnoea is 
the most significant symptom in the dying. The 
mode of death was described in two papers and is 
predominantly through respiratory or heart failure.
conclusions There remains a dearth of 
information regarding symptom burden and 
mode of death to inform decisions regarding 
end- of- life care in patients dying with COVID-19. 
Rapid data gathering on the mode of death and 
the profile of symptoms in the dying and their 
prevalence and severity in areas where COVID-19 
is prevalent will provide important intelligence 
for clinicians. This should be done urgently, 
within ethical norms and the practicalities of a 
public health, clinical and logistical emergency.
IntroductIon
Since first reported in December 2019 
in Wuhan, China, coronavirus disease 
2019 (COVID-19) has spread rapidly, 
with over 2 million confirmed cases 
globally. Originally, it was named severe 
acute respiratory syndrome coronavirus 
2 (SARS- CoV-2) due to phylogenetic and 
clinical similarities to the severe acute 
respiratory syndrome coronavirus. The 
pathogen has now been identified as 
highly contagious novel enveloped RNA 
betacoronavirus. Most experience mild 
symptoms, yet 6% of cases will be criti-
cally ill.1 Mortality rates vary regionally, 
but the WHO estimates a global mortality 
of about 3% of confirmed cases.2
The COVID-19 pandemic has created 
unprecedented need for information. It 
is the cause of significant mortality, and 
there is a need for rapidly disseminated 
information about symptom prevalence 
and intensity, resistance or susceptibility 
to symptom control and mode of death. 
We undertook a symptomatic literature 
review to inform palliative and end- of- life 
care.
Methodology
A rapid literature review was completed 
over a 3- month period in 2020. Rapid 
reviews streamline systematic review 
methods to synthesise evidence in a short 
timeframe, particularly in understudied 
topics. As with systematic reviews, a rapid 
review follows a structured approach to 
search and evaluate the literature, but the 
review steps may vary in comprehensive-
ness due to the timeframe.3 Our approach 
was comprehensive and only differed 
from a systematic review in simplified data 
presentation and elimination of marginal 
or grey literature.4 5 Symptom preva-
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Table 1 COVID19 symptoms in decedents and survivors
ISS (Italy)7 
n=6801
Guan et al11 
n=1099
Deng et al8 
n=225
Zhou et al14 
n=191
Wang et al15 
n=138
Liu et al16 
n=137
Xu et al17 
n=62
Yang et al9 
n=52
Huang et al18 
n=41
Chang et al19 
n=13
Breathlessness/dyspnoea 71% 18% 45% No data 31% 19% No data 64% 55% No data
Cough 40% 68% 38% 79% 59% 48% 81% 77% 76% 46%
Diarrhoea 6% 4% 15% 5% 10% 8% 8% No data 3% 8%
Expectoration No data 34% 22% 23% 27% 4% 56% No data 38% No data
Fatigue No data 38% No data 23% 70% 32% 52%* 20%† 44%* No data
Haemoptysis 1% 1% 3% No data No data 5% 3% No data 8% No data
Myalgia No data 15% 25% 15% 35% 32% 52%* 12% 44% 23%
Nausea/vomiting No data 5% No data 4% 14%‡ No data No data 4% No data No data
Palpitations No data No data 11% No data No data 7% No data No data No data No data
Upper airway congestion No data 5% No data No data No data No data No data 6% No data 62%
*Huang et al, Liu et al and Xu et al list myalgia or fatigue.
†Listed as ‘malaise’ in Yang et al.
‡Wang et al list nausea and vomiting separately.













Agitation No data No data No data 43%
Cough 40% 43% 75% 4%
Delirium No data No data No data 24%
Diarrhoea 6% 17% No data 3%
Dyspnoea 71% 71% 60% 67%
Expectoration/secretions No data 32% No data 11%
Fatigue No data 20%* No data 9%
Haemoptysis 1% 5% No data No data
Headache No data 6% 5% No data
Pain No data No data 10%† 23%
Palpitations No data 10% No data No data
Vomiting No data No data 5% No data
*Listed as ‘malaise’ in Yang et al.
†Arthralgia and chest pain.
literature search
Relevant publications in English were located through 
a literature search from 1 January to 23 March 2020 
and subsequent weekly autosearches in PubMed (to 21 
April 2020). To address symptom burden and clinical 
profile in those dying from COVID-19, a combination 
of database- specific subject headings and keywords 
was used in the search. We used the following search 
terms: [COVID* [OR] CORONAVIRUS* [OR] 
SARS- CoV2] AND [SYMPTOM*]. This covered 
the symptom burden associated from COVID-19 
and care of the dying. No date limits were applied. 
Specific study types (case reports, case–control studies, 
cohort studies, clinical trials and systematic reviews) 
were incorporated into the searches of Embase, Ovid 
MEDLINE, Journals@Ovid, NHS Scotland Jour-
nals@Ovid and the Cochrane Library. A second search 
of the same databases adopted wide search criteria to 
capture symptom prevalence and management data. 
This second search was to capture data on cause and 
mode of death and used the search terms: [COVID* 
[OR] CORONAVIRIUS* [OR] SARS- CoVI2] AND 
[DEATH* [OR] DYING* [OR] PALLIATIVE [OR] 
HOSPICE [OR] END OF LIFE].
In addition, a hand search of original and review 
articles was conducted as an additional measure to 
ensure quality and comprehensiveness.
study selection
Two independent assessors (PWK and SIRN) screened 
results by review of titles and abstract and applied 
inclusion/exclusion criteria. After that, weekly auto-
searches continued for a further 4 weeks. A further 
paper was identified as an article in press. Prospec-
tive or retrospective cohort studies were included of 
adult patients with COVID-19, SARS- CoV-2 or coro-
navirus. Study outcomes: symptoms on all patients 
(survivors or those dying), mode of death and symp-
toms of patients who died. We included only studies 
published in English. Paediatric studies were excluded.
results
The search found a total of 118 papers and reports 
of which 12 met the inclusion criteria: 10 had data 
on overall symptoms, 4 had discrete symptom data for 
those who died and 2 had data about the cause or mode 
of death. The paucity of studies, all produced for rapid 
publication, most within 2 months of data collection 
and the limited scope of the data meant meta- analysis 
was impossible. Data were heterogeneous in collection 
and mostly at presentation but gave some informa-
tion about the dying. One paper with useful data on 
COVID-19 symptoms disappeared from the original 
publication site, withdrawn by the authors.6
The data are presented in tables 1–4 below.
Four papers7–10 give data about symptoms discretely 
as in non- surviving patients, though in three of these 
it is unclear whether these are presenting symptoms 
or in the dying4 10 11 (see table 2). The symptoms are 
ordered in order of their prevalence. No data were 
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Table 3 Modes of death
Modes of death n=109 %
Acute respiratory distress syndrome 98 90
Acute cardiac injury 65 60
Acute kidney injury 20 18
Shock 13 12
Disseminated intravascular coagulation 7 6
Deng et al.8
Table 4 Cause or mode of death
Cause or mode of death n=68 %
Respiratory failure 36 53
Myocardial damage/failure 22 33
Respiratory failure with myocardial damage/failure 5 7
Unknown 5 7
Ruan et al.12
symptoms. Dyspnoea, cough and fatigue feature most 
prominently as common symptoms. Other symptoms 
(e.g., myalgia or headache) appear to be presenting 
features given their consistency across all symptom 
reporting survivors and deaths.
The prevalence of cough and dyspnoea in the 
dying is evident from the data above (more from the 
palliative focus of the Italian data and the size of the 
sample). Symptom classification more familiar to palli-
ative physicians is found in the most recent retrospec-
tive study by Lovell et al.10
Mode of death
Only two papers give useful data about the mode of 
death.8 12 One study lists several complications in those 
who died, which perhaps contributed to or were the 
mode of death8 (see table 3). The second gives data on 
the cause of death12 (see table 4).
dIscussIon
The COVID-19 pandemic has changed how society 
functions, setting challenges and changes for health 
services rarely seen outside war time. The prioritisa-
tion of emergency care, acute medicine and critical 
care/intensive care services has resulted in staff of all 
professions downing the usual tools of their trade to 
contribute wherever their time is best needed. Many 
have required additional training and ongoing super-
vision in new environments. Palliative care is one 
specialty that has not seen staff deployed elsewhere; as 
COVID-19 related deaths rise, the need for expertise 
in symptom control care of the dying has never been 
more apparent. However, expertise must be respon-
sive, pragmatic and innovative. The harsh reality is 
that the availability of important drugs, suitable infu-
sion systems and loved one’s presence at the time of 
the death will all become challenges.
This rapid review has collated the evidence from 
the first weeks of the pandemic. The aim is to inform 
clinical practice with preliminary pointer to the likely 
symptoms and clinical trajectories encountered that 
may allow prognostication and effective communi-
cation with patients and families. It appears most die 
with either respiratory or cardiac failure/injury or 
both. As one might expect in acutely unwell—patients 
with infection sepsis, liver failure and disseminated 
intravascular coagulation—there will be elements of 
multiple organ damage leading to death. This will have 
implications for the metabolism and clearance of many 
of the common agents used in end- of- life care.
In many countries this has been a public health and 
medical emergency and patient protection and treat-
ment the primary concern for services and clinicians. 
In this situation, the collection of clinical data is diffi-
cult, both ethically and practically. Reporting may also 
bound by the local medical culture. There are signifi-
cant differences in the services and culture of palliative 
care in China, Italy and the UK, the countries from 
which the papers we report originate. In addition, 
health data reporting in an authoritarian state is very 
different from that in a liberal democracy (which may, 
or may not, explain the disappearance within a week 
of data from Du et al,6 previously available from The 
Lancet).
The review we conducted should prompt urgent 
prospective data collection in countries where 
COVID-19 is endemic and patients presenting with 
symptoms. Given the evident rapidity of the terminal 
phase, understanding the symptoms in the cohort 
unlikely to survive and their susceptibility to pharma-
cological (or other) measures will allow clinicians to 
direct appropriate management. Similarly, the terminal 
phase trajectory allows clear communication with rela-
tives and carers to prepare for death.
The focus of rapid information gathering from areas 
affected by COVID-19 has been on clinical issues 
related to ventilator support, survival and potential 
treatments. The rush for data in the short time since 
the first cases were reported is less than 16 weeks. 
The emphasis has been anywhere but on palliation 
in the midst of a public health crisis. Of note is the 
fact that a search combining CORONAVIRUS or 
COVID* OR SARS- CoV2 AND palliative yielded no 
relevant results for the initial period. It is unclear what 
the setting of the deaths in the review were (intensive 
care units, high dependency units or general wards). 
There were no data evident from settings other than 
secondary or tertiary care. There was a glaring dearth 
of data for some symptoms, the most obvious being 
delirium or agitation, given that this is prevalent in 
acutely illness, especially in the elderly.13 The absence 
raises questions about data collection techniques and 
the focus on presenting rather that chronic or terminal 
symptoms. Dyspnoea may be reported as a proxy for 
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where data are collected by palliative physicians.10 
Consistency of terms is difficult where studies are 
heterogeneous, and it may be that there are cultural 
limitations to data collection. It is noteworthy that no 
study specially accounted for comorbidities within the 
symptom groups. We can only surmise that those with 
pre- existing lung disease experience more dyspnoea 
and those with heart disease experience more palpi-
tations. Rather than developing risk factors for poorer 
prognosis, this might help develop risk profiles for 
symptom load in the dying.
conclusIons
Our data indicate that cough, breathlessness, fatigue 
and myalgia are significant symptoms in people hospi-
talised with COVID-19. Dyspnoea is the most signif-
icant symptom in the dying. The mode of death is 
predominantly through respiratory or heart failure or 
both. No data are evident on dying trajectories.
Rapid data gathering on the mode of death and 
the symptoms burden in dying patients (prevalence 
and where possible data refractions) in areas where 
COVID-19 is prevalent will provide important intel-
ligence for clinicians. This should be undertaken 
urgently, within ethical norms, and the practicalities 
of dealing with a public health, clinical and logistical 
emergency.
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